Early Parkinson's patients waiting too long to seek medical evaluation

September 27, 2018, University of South Florida
Figure 1. Relationship between time of diagnosis, need for symptomatic therapy and the opportunity for a patient to participate in an early PD disease modifying therapy trial. Credit: University of South Florida

The time between diagnosis and the institution of symptomatic treatment is critical in the effort to find a cure for Parkinson's Disease (PD). A paper published in Nature Partner Journal: Parkinson's Disease notes too many early PD patients wait too long before seeking medical attention, or start taking symptomatic medications before they are required, thereby dramatically shrinking the pool of candidates for clinical trials.

Parkinson's disease is a disorder of the central nervous system that affects . Symptoms include tremors, stiffness, and slow and small movement. The pace of progression varies among patients, making the months following diagnosis crucial to researchers studying the disease's progression.

"The critical time of about one year from when the patient can be diagnosed with early PD based on mild classic motor features until they truly require symptomatic therapy can be considered the Golden Year," said lead author Robert A. Hauser, MD, director of the Parkinson's & Movement Disorder Center at the University of South Florida. "It is during this early, untreated phase, that progression of clinical symptoms reflects the progression of the underlying disease."

Hauser says that in order to determine whether or not a potential disease slowing therapy is actually working, they must be able to compare the therapy to a placebo without interference from symptomatic treatment. Otherwise, they won't know if the therapy is slowing the disease's progression or if they are just seeing the effects of symptomatic treatment.

This requires patients to seek assessment soon after they notice the onset of tremor or slow movement. In addition, physicians should consider referring patients to clinical trials soon after diagnosis and delay prescribing symptomatic medication until it's necessary. If a patient waits until symptomatic is necessary, the opportunity to participate in these crucial is lost.

Explore further: DBS treatment may slow the progression of Parkinson's tremor in early-stage patients

More information: Robert A. Hauser. Help cure Parkinson's disease: please don't waste the Golden Year, npj Parkinson's Disease (2018). DOI: 10.1038/s41531-018-0065-1

Related Stories

DBS treatment may slow the progression of Parkinson's tremor in early-stage patients

June 29, 2018
Deep brain stimulation (DBS) may slow the progression of tremor for early-stage Parkinson's disease patients, according to a Vanderbilt University Medical Center study released in the June 29 online issue of Neurology, the ...

Researchers buoyed by molecule's potential to slow Parkinson's progress

January 26, 2017
A naturally occurring molecule in the brain, when used as a therapy, may hold a key to stopping the progression of Parkinson's disease, new research has found.

Breakthrough measures Parkinson's progression in the brain

May 26, 2015
University of Florida researchers have identified a biomarker that shows the progression of Parkinson's disease in the brain, opening the door to better diagnosis and treatment of the degenerative disease.

Researchers look for clues to progression of Parkinson's disease

July 19, 2013
Emory researchers are conducting a prospective clinical study to examine the possibility of diagnosing Parkinson's disease (PD) before motor symptoms occur. The study is an arm of the Parkinson's Progression Markers Initiative ...

Recommended for you

Growing a brain: Two-step control mechanism identified in mouse stem cells

December 17, 2018
Scientists have identified two distinct control mechanisms in the developmental transition of undifferentiated stem cells into healthy brain cells. This fundamental research using mice may inform regenerative medicine treatments ...

Two compounds in coffee may team up to fight Parkinson's

December 10, 2018
Rutgers scientists have found a compound in coffee that may team up with caffeine to fight Parkinson's disease and Lewy body dementia—two progressive and currently incurable diseases associated with brain degeneration.

New Parkinson's disease drug target revealed through study of fatty acids

December 4, 2018
The human brain is rich in lipids. Investigators studying Parkinson's disease (PD) have become increasingly interested in lipids since both molecular and genetic studies have pointed to the disruption of the balance of the ...

A toxin that travels from stomach to brain may trigger Parkinsonism

December 4, 2018
Combining low doses of a toxic herbicide with sugar-binding proteins called lectins may trigger Parkinsonism—symptoms typical of Parkinson's disease like body tremors and slowing of body motions—after the toxin travels ...

Experimental cancer drug shows promise for Parkinson's

December 3, 2018
The study, funded by Parkinson's UK, suggests that the drug, tasquinimod, which is not yet on the market, works by controlling genes that may cause Parkinson's. This happens when the drug interacts with a protein inside brain ...

Parkinson's therapy creates new brain circuits for motor function, study finds

November 28, 2018
Scientists have uncovered that an emerging gene therapy for Parkinson's disease creates new circuits in the brain associated with improved motor movement. These findings, published today in Science Translational Medicine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.